Flashpoint Therapeutics, a Chicago, IL-based company developing nanotechnology-enabled therapeutics for cancer and other diseases, raised $10M in Seed funding.
The round was led by Beta Lab, with participation from private equity investor Russell Carson’s CS Venture Opportunities Fund.
The company intends to use the funds to advance its first therapeutic candidate in oncology, nominate a second development candidate, and advance multiple internal and partnered discovery programs. Flashpoint will also use the funds to expand its team and enhance the platform to develop multi-targeted RNA, CRISPR and peptide therapeutics with unique characteristics.
Led by Adam Margolin, Ph.D., CEO & Founder, Flashpoint Therapeutics provides an approach to designing cancer immunotherapies that transform therapeutic components from ineffective to curative through optimized nanoscale architecture. Its nanotechnology-based discovery platform enables more potent multi-targeted therapies by co-delivering diverse RNA, DNA, and peptide cargo to the right cells with precise control of stoichiometry, optimized structure-function relationship and synchronized activation kinetics. Flashpoint immunotherapies have shown promise for treating breast cancer, lymphoma, cervical cancer, melanoma, colon cancer, glioma, and prostate cancer. Based on these studies, the company will advance the best of these candidates into clinical trials.
FinSMEs
25/10/2023